Gefitinib (Iressa; AstraZeneca Pharmaceuticals, Wilmington, DE) is an oral epidermal growth
factor receptor tyrosine kinase inhibitor (EGFR-TKI) with favorable toxicity and antitumor …

PURPOSE: The epidermal growth factor receptor inhibitors, gefitinib and erlotinib, are used
as standard salvage therapy for advanced non-small-cell lung cancer (NSCLC). The aim of …

Gefitinib, an epidermal growth factor tyrosine kinase inhibitor (EGFR-TKI), has been
approved in Japan for the treatment of patients with advanced non-small-cell lung cancer …

BACKGROUND This is the first report of long‐term (> 10 years) safety, tolerability, and
survival data on patients with non–small cell lung cancer (NSCLC) who received treatment …

Epidermal growth factor receptor tyrosine kinase inhibitors represent a new treatment option
for patients with advanced nonsmall cell lung cancer (NSCLC). This retrospective study …

Purpose: Most lung cancers with activating epidermal growth factor receptor (EGFR)
mutations respond to gefitinib; however, resistance to this tyrosine kinase inhibitor (TKI) …

Inhibition of epidermal growth factor receptor (EGFR) has become an important target in the
treatment of advanced non-small cell lung cancer (NSCLC). Erlotinib and gefitinib, two small …

Background Inhibition of the epidermal growth factor receptor pathway with tyro-sine kinase
inhibitors can improve outcome of patients with advanced non-small cell lung cancer after …

Background: In epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer
(NSCLC), the tyrosine-kinase inhibitor gefitinib is in broad use. We retrospectively analysed …

Background A clinical trial that compared erlotinib with a placebo for non–small-cell lung
cancer demonstrated a survival benefit for erlotinib. We used tumor-biopsy samples from …